Immediate Impact
1 by Nobel laureates 63 standout
Citing Papers
New epilepsy therapies in development
2024 Standout
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Works of Chun‐Lan Chang being referenced
Economic impact of tobramycin in patients with cystic fibrosis in a managed care population
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Chun‐Lan Chang | 69 | 31 | 52 | 109 | 95 | 27 | 392 | |
| Shangyi Jin | 69 | 41 | 44 | 188 | 63 | 22 | 441 | |
| Anju Parthan | 21 | 8 | 125 | 72 | 115 | 37 | 454 | |
| RM Herings | 43 | 4 | 49 | 29 | 21 | 20 | 374 | |
| Nasrin Mansournia | 42 | 6 | 33 | 22 | 53 | 28 | 456 | |
| Rebecca Persson | 70 | 6 | 45 | 66 | 13 | 29 | 390 | |
| Lotfi Chalabi | 38 | 2 | 54 | 21 | 51 | 14 | 452 | |
| Katherine D. Wysham | 12 | 41 | 179 | 56 | 35 | 345 | ||
| Paijit Asavatanabodee | 10 | 22 | 22 | 207 | 36 | 21 | 384 | |
| Diane McNally | 18 | 19 | 53 | 76 | 8 | 23 | 370 | |
| Thy P. | 33 | 1 | 63 | 20 | 107 | 13 | 448 |
All Works
Loading papers...